Key Takeaways Viking Therapeutics reported a Q3 loss of 0.81 per share, missing the consensus estimate.R&D expenses rose sharply to 90M, driven by clinical and manufacturing costs.The company advanced VK2735 obesity studies and delayed an IND filing to early 2026.Viking Therapeutics (VKTX) reported a third-quarter 2025 loss of 81 cents per share, wider than the Zacks Consensus Estimate of a loss of 70 cents. The company had incurred a loss of 22 cents per share in the year-ago quarter.Currently, Viking Th ...